Biblio

Filters: Author is Moorman, Anthony V [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

C

O'Connor D, Demeulemeester J, Conde L, Kirkwood A, Fung K, Papaleonidopoulou F, Bloye G, Farah N, Rahman S, Hancock J, et al. The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2023:JCO2202734.

D

Hunger SP, Tran THoa, Saha V, Devidas M, Valsecchi MGrazia, Gastier-Foster JM, Cazzaniga G, Reshmi SC, Borowitz MJ, Moorman AV, et al. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023;10(7):e510-e520.

G

Fischer U, Förster M, Rinaldi A, Risch T, Sungalee S, Warnatz H-J, Bornhauser B, Gombert M, Kratsch C, Stütz AM, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015.

H

Pal D, Blair H, Parker J, Hockney S, Beckett M, Singh M, Tirtakusuma R, Nelson R, McNeill H, Angel SH, et al. hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Cell Rep Med. 2022;3(8):100717.

I

Marks DI, Clifton-Hadley L, Copland M, Hussain J, Menne TF, McMillan A, Moorman AV, Morley N, Okasha D, Patel B, et al. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. Lancet Haematol. 2022;9(4):e276-e288.

O

Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, Imai C, de Moerloose B, Schmiegelow K, Burns MA, et al. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials. J Clin Oncol. 2023:JCO2300088.

R

Eckert C, Parker C, Moorman AV, Irving JAe, Kirschner-Schwabe R, Groeneveld-Krentz S, Révész T, Hoogerbrugge P, Hancock J, Sutton R, et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021;151:175-189.

T

Bell HL, Blair HJ, Singh M, Moorman AV, Heidenreich O, van Delft FW, Lunec J, Irving JAE. Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Cancer Cell Int. 2023;23(1):202.